Breast Cancer dataset; two distinct cohorts have been prepared including (1) patients with confirmed cancer positive with associated follow-up study at 6 months (2) patients with confirmed cancer negative in associated follow-up study at 24 months.
For this Breast Cancer dataset,two distinct cohorts have been prepared including (1) patients with confirmed cancer positive with associated follow-up study at 6 months (2) patients with confirmed cancer negative in associated follow-up study at 24 months.
Each patient study includes full field digital mammography (FFDM) with full Breast series. The studies have been acquired from a variety of imaging hardware including Hologic, GE and Seimens. The datasets include diverse ethnicity to reduce bias.
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 1,400 healthcare sites through its iRWD platform. This isn't just data, its the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
We are providing a free sample from each cohort. If you require additional data or data enrichment or have any questions, please contact us directly at sales@onemednet.com.
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
This listing has one pricing dimension: Product Access, measured in Units. It is offered free of charge. The dimension grants subscribers access to the de-identified mammography and breast cancer medical imaging dataset. There are no tiers, instance sizes, or usage add-ons to choose from. You subscribe to gain access, and the single unit-based dimension covers that access. This sample dataset lets you evaluate the data before pursuing broader data needs through the vendor.
Top-of-mind questions for buyers
What counts as one Unit of Product Access for this dataset?
A Unit grants you subscriber access to the de-identified mammography and breast cancer imaging dataset. It is an access credential, not a per-image or per-record count. One subscription covers your access to the sample dataset during the subscription period.
How long does my access last, and what happens when the term ends?
This is a sample published dataset offered as a one-month subscription. Access covers that period. To follow cohorts over time or pull continuous, longitudinal updates, you contact the vendor to arrange broader real-time data needs beyond this free sample.
Are there extra charges once I subscribe to this dataset?
No. The single Product Access dimension is free of charge. There are no tiers, usage add-ons, or per-record fees. Subscribing grants access to the sample dataset for evaluation. Broader or ongoing data delivery is handled separately through the vendor.
www.onemednet.com
Helpful?
Vendor refund policy
Refunds not available for this offer.
How can we make this page better?
Tell us how we can improve this page, or report an issue with this product.
Give us feedbackReport a problem with this product or seller
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA).
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
CancerVision is a cutting-edge 2-in-1 whole-genome cancer assay offering both somatic (40x) and paired germline (20x) coverage, with ultra-deep targeting (500x) of 600+ clinically relevant cancer genes. It delivers >99% sensitivity and PPV, with robust detection of complex variants including SVs, CNVs, and mutations in non-coding regions. CancerVision also provides key biomarker insights such as TMB, MSI, HRD, mutational signatures, and germline variants. This CAP/CLIA-validated assay offers a fast 2-week turnaround and supports advanced custom analyses, including ecDNA, tumor ploidy, and transposable element detection, at whole-genome resolution. Designed for precision oncology, CancerVision is your comprehensive genomic solution for cancer diagnostics and research.
Open-source NER model for cancer genetics entities in biomedical and clinical text. Trained on BioNLP2013-CG and optimized for state-of-the-art precision, it enables reliable extraction with fast, easy deployment via Hugging Face Transformers.